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ABSTRACT
Introduction: The long-term success of non-surgical
weight loss treatment in adults with obesity is limited
by substantial relapse, and only a few evidence-based
weight loss maintenance treatments exist. This clinical
trial investigates the feasibility and efficacy of a social
facilitation maintenance programme for weight loss
maintenance, tailored to meet the needs of obese
adults who have undergone a lifestyle weight loss
intervention.
Methods and analysis: In a single-centre, open
feasibility trial, 72 adults currently or previously obese
or overweight who have undergone a lifestyle weight
loss intervention are centrally randomised to 4 months
of social facilitation maintenance treatment or treatment
as a usual control condition. In 16 outpatient group
sessions, the social facilitation maintenance treatment,
based on a socioecological model and on evidence
supporting social facilitation as a key process in
maintaining weight loss, focuses on promoting
interpersonal relationships to build up a healthy
lifestyle for long-term weight loss maintenance.
Primary outcome is the amount of weight regain at
6-month follow-up, compared with pre-treatment
weight, derived from measured body weight.
Secondary outcomes address feasibility, including
recruitment, attrition, assessment non-completion,
compliance and patients’ programme evaluation; and in
comparison with pre-weight loss maintenance, social
and interpersonal functioning, eating behaviour and
physical activity, psychological and physical symptoms,
body composition and risk of comorbidity, and quality
of life at post-treatment and follow-up assessments.
Ethics and dissemination: The study was approved
by the Ethical Committee at the University of Leipzig
(165-13-15072013). The study results will be
disseminated through peer-reviewed publications.
Trial registration number: DRKS00005182.
BACKGROUND
Prevalence rates for obesity and overweight
in adults have increased over the prior
decades.1 2 Obesity is a leading cause of mor-
tality and health-related disorders, such as
type 2 diabetes mellitus and coronary heart
disease.3 4 The majority of comorbidities are
alleviated by modest weight loss (WL).5–7
However, it is not the attained body mass
index (BMI, kg/m2) itself, but the successful
long-term maintenance of the reduced
weight that is most important for the reduc-
tion of obesity-related health risks.8 Meta-
analyses, however, suggest that in the long
run, the majority of adult patients in WL
programmes regain most of the weight ini-
tially lost.9 10 This turns WL maintenance
(WLM) into a major challenge in obesity
management.
Reviews on the efﬁcacy of WLM pro-
grammes provide evidence of the efﬁcacy of
behavioural interventions,9 11 12 although a
delayed weight regain may occur. Predictor
analyses indicate that psychosocial problems
that often co-occur with obesity, including a
lack of social support, social isolation, in-
terpersonal distress, low self-esteem, low self-
efﬁcacy and decreased coping skills, represent
major barriers to WLM.13–16 Their import-
ance for maintaining behaviour change in
WLM, through fostering self-motivation,
seems to exceed that for initiating behaviour
change in WL.17 Several studies have docu-
mented psychosocial and interpersonal
Strengths and limitations of this study
▪ The strengths of this study are the randomised-
controlled evaluation of the feasibility and effi-
cacy of a weight loss maintenance treatment in
adults with obesity that has a unique focus on
the social network and has been proven to be
efficacious in children with obesity.
▪ The SPIRIT guidelines are followed.
▪ Limitations are inherent to the feasibility focus of
this study and include the single-centre conduct,
small sample size, no stratification for prior
weight loss, treatment through one therapist and
no blinding of treatment to raters.
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difﬁculties encountered by obese individuals, especially in
clinical settings.18 Obese individuals face stigma and nega-
tive social interactions with strangers, acquaintances and
friends in multiple domains of life,19 which may lead to
social isolation and withdrawal.20 21 Furthermore, social
impairments are frequent (eg, low socioeconomic status,
poor neighbourhoods).22 These disadvantages are distres-
sing and may be relevant from a psychopathological per-
spective, likely impairing weight management.23 24 In
contrast, an extended focus on weight maintenance skills
is central for effective WLM. Healthy eating behaviours
(eg, regular meal patterns), self-monitoring, internal
control of eating behaviour and sustained physical activity
have shown positive effects on WLM.14 15 25 Therefore,
improving psychosocial problems and weight mainten-
ance skills may be beneﬁcial for WLM.
Most WLM programmes focus on weight maintenance
skills in the individual patient, while psychosocial pro-
blems and difﬁculties within the social network are
usually not comprehensively addressed.17 26 The socio-
ecological model posits that facilitating factors and bar-
riers of one’s behaviour reside on multiple levels27—
intrapersonal, interpersonal, social network and commu-
nity. Social facilitation focuses on the enhancement of
performance through interindividual inﬂuences such as
the presence of others or modelling effects.28 Based on
these concepts, and against the background of the efﬁ-
cacy of interpersonal psychotherapy for stabilising body
weight in eating and overweight disorders,29–31 a social
facilitation maintenance (SFM) programme for WLM
was developed for children using empirically supported
techniques to facilitate social networks that support
healthy eating and physical activity.32 The SFM approach
also targets interpersonal and intrapersonal factors iden-
tiﬁed as barriers to a healthy lifestyle. In a randomised-
controlled comparison of an SFM programme, a ‘trad-
itional’ behavioural management and a no-treatment
control group, children aged 7–12 years in both active
treatments maintained their relative weight better than
children in the control group with medium-to-large
effect sizes.32 During the 2 years of follow-up, both active
maintenance treatments’ efﬁcacy relative to the
no-treatment control group declined, but the effects of
SFM alone were signiﬁcantly better than those of the
no-treatment control group (d=0.45). There was
indication that social problems moderated the relative
weight change from baseline to 2 years of follow-up, with
low social problem children in SFM versus the control
group having the best outcomes. Although these results
are promising and a family-based follow-up trial and an
employee wellness application are underway,33 34 SFM has
not yet been adapted and evaluated for WLM in adults.
Since the medical comorbidities of obesity increase
healthcare costs,35 36 WLM treatment with a focus on
psychosocial problems has the potential to reduce these
costs. It is thus a clinical and research priority to evaluate
WLM treatments such as SFM treatment. In this context,
the aim of this study is to evaluate the feasibility and
efﬁcacy of SFM treatment for WLM in adults, relative to
treatment as usual (TAU), in an exploratory, single-
centre randomised trial. Additional objectives are to iden-
tify changes in: social and interpersonal functioning;
eating behaviour and physical activity; psychological
and physical symptoms; body composition and risk of
comorbidity; and quality of life. Pre-treatment and socio-
demographic variables, compliance, and patient motiv-
ation and expectation will be considered as outcome
predictors. TAU was selected as the control condition for
this ﬁrst evaluation of feasibility and efﬁcacy of an
evidence-based child-focused programme in an
adult-adapted version.
METHODS AND ANALYSIS
Hypotheses
1. Patients receiving SFM treatment will sustain larger
amounts of WL compared with patients receiving
TAU at 6-month follow-up.
2. SFM treatment in adults will be feasible.
3. Patients receiving SFM treatment will sustain larger
amounts of WL at post-treatment and at 12-month and
24-month follow-up and will show greater improvements
in health at post-treatment and follow-up assessments.
Design, participants and procedures
Study design
SFM treatment for adults is an exploratory, single-centre,
open (ie, not blinded), prospective randomised trial,
evaluating the feasibility and efﬁcacy of SFM treatment
(experimental condition) compared with TAU (control
condition). The study design is depicted in ﬁgure 1. The
study period lasts 4 months per patient in both conditions
(4 months of SFM treatment and TAU, respectively).
Following a lifestyle WL intervention, patients undergo a
pre-treatment assessment (t0). Following SFM or TAU as
WLM treatment over 4 months, a post-treatment assess-
ment is conducted (t1), followed by 6-month (t2),
12-month (t3) and 24-month (t4) follow-up assessments.
Participants
A total of 72 adult patients within the lifestyle WL inter-
vention are randomised to either SFM treatment or TAU.
Inclusion criteria are summarised in box 1. To ensure
generalisation of study results, exclusion criteria are kept
to a minimum.
Recruitment
The ongoing study is conducted from September 2013
to June 2017 at the outpatient unit of the Integrated
Research and Treatment Center (IFB) AdiposityDiseases
at University of Leipzig Medical Center, Leipzig,
Germany. All patients presenting at the IFB outpatient
unit for lifestyle WL intervention and having consented
to be contacted for participation in research studies are
informed about the study and, if interested, screened for
eligibility by telephone (-t2). They are offered—with a
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50% chance—intensive WLM treatment at no cost, and
ﬁnancial incentives for participation in 12-month and
24-month follow-up assessments (t3, t4 à €15). The life-
style WL treatment at the IFB outpatient unit requires
BMI≥35.0 kg/m2 for admission. The WL treatment is
provided under medical supervision, focuses on diet and
nutrition, and includes one consultation with a physician;
three 60 min individual and six 90 min nutritional coun-
selling sessions with a nutritionist in groups of 6–10
patients; and 60 min weekly or semiweekly group-based
exercise sessions for strength and/or endurance training.
Procedures
During telephone screening (-t2), eligible patients are
invited to a preparatory session (-t1). At this session, inclu-
sion and exclusion criteria are evaluated, written informed
consent is obtained, and patients are enrolled and cen-
trally randomised into the SFM or TAU arm by trained
study staff. After ﬁnishing the lifestyle WL intervention, a
pre-treatment assessment (t0) is conducted during which
sociodemographic, anamnestic, anthropometric and clin-
ical data are obtained using self-report questionnaires and
objective measurement. Both SFM treatment and TAU are
conducted over a 4-month period.
Ancillary study
An ancillary study investigates changes in proinﬂamma-
tory cytokines, serotonin transporter availability and
sleep ratings as predictors of weight change over SFM
treatment (principal investigator: Hubertus Himmerich,
MD). This study involves a separate consent procedure
for voluntary participation offered to all patients at the
preparatory session, and blood sampling and sleep-
related self-report questionnaires at pre-treatment (t0)
and post-treatment (t1).
Intervention
Experimental intervention—SFM
For development of the SFM manual for adults, the
existing evidence-supported SFM intervention manual
for children by Wilﬂey et al32 was used. SFM treatment is
based on the socioecological model,27 targeting intraper-
sonal and interpersonal factors identiﬁed as barriers to a
healthy lifestyle in order to facilitate social networks that
support healthy eating and physical activity.32 For this
study, the SFM manual for children was reorganised and
shortened in order to ﬁt with the group format. Content
of sessions was adapted to adults and German culture,
and interventions to foster group cohesion were added
(eg, group-based games).
Figure 1 Schedule of enrolment, interventions and assessments. t1, post-treatment; t2, 6-month follow-up; t3, 12-month
follow-up; t4, 24-month follow-up.
Box 1 Inclusion and exclusion criteria
Inclusion
▸ Age ≥18 years;
▸ 25.0 kg/m2≤ body mass index ≤45.0 kg/m2;
▸ Previous lifestyle weight loss intervention at the Integrated
Research and Treatment Center AdiposityDiseases (IFB) out-
patient unit with ≥50% attendance;
▸ Sufficient German language skills.
Exclusion
▸ Serious unstable somatic conditions (eg, cardiovascular
disease);
▸ Serious mental conditions (eg, psychotic disorder, suicidality);
▸ Bariatric surgery;
▸ Use of weight-impacting medication (eg, antipsychotics);
▸ Current psychotherapy;
▸ Current pregnancy or lactation.
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The overarching goal of SFM for adults is to promote
interpersonal relationships to strengthen a healthy life-
style (eating behaviour and physical activity) for long-
term WLM. Therapeutic phases, sessions and topics are
depicted in table 1. The treatment consists of four
phases with a focus on: (1) the patients themselves, (2)
the patients’ signiﬁcant others and (3) the community
(eg, work setting, neighbourhood). The treatment is (4)
concluded by a consolidation and relapse prevention
phase. The ﬁrst phase (sessions 1–4) guides patients to
review their eating behaviour and physical activity rou-
tines for long-term WLM, and addresses changes in the
physical and social home environment. The second
phase (sessions 5–8) focuses on changes in the social
network fostering healthful eating and physical activity.
The third phase (sessions 9–11) addresses changes in
the work environment and neighbourhood, with a con-
centration on the promotion of social physical activity.
The fourth phase (sessions 12–16) focuses on coping
with weight-related stigma as a barrier to healthful eating
and physical activity, on the consolidation of therapeutic
gains and on the management of anticipated relapse.
Across these phases, interpersonal problems (eg, lack of
social support, communication problems, stigma) and
intrapersonal problems (eg, negative thinking, self-stigma,
negative body image) are addressed.
SFM treatment is delivered in groups of 6–10 patients
within 16 weekly sessions of 2 hours duration. It is
provided by a psychologist with training in behaviour
therapy and, speciﬁcally, SFM. Empirically supported
therapeutic techniques are used (eg, psychoeducation,
self-monitoring, goal setting, self-reinforcement, problem-
solving, communication training). Major differences
between the adult SFM manual and the child SFM
manual reside in structure and content (eg, group
therapy vs combined family and individual therapy; tailor-
ing of exercises to group format; and adult-relevant
topics, eg, work setting). Treatment ﬁdelity is ensured
through regular supervision, also preventing a drift in
treatment delivery.
Control intervention—TAU
The TAU control condition consists of one visit with a
physician, and up to ﬁve 60 min individual nutritional
Table 1 Therapeutic phases, sessions and topics
Phase Sessions Topics
Focus on self (1) Introduction ▸ Introduction
▸ Socioecological model
(2) Healthy behaviours ▸ Meal routines
▸ Physical activity and sleep routines
(3) Healthy home
environment
▸ Barriers and resources at home
▸ Social support at home
▸ Communication training
(4) Self-reinforcement ▸ Negative thinking and self-verbalisations
Focus on significant others (5) Social network support ▸ Barriers and resources in the social network
(6) Changing the social
network
▸ Planning and initiation of change regarding healthy
eating and physical activity
(7) Healthy meetings ▸ Arrange meetings in a healthy way regarding eating
and physical activity
(8) Communication ▸ Initiating and maintaining friendships
▸ Communication training
Focus on community (9) Work environment ▸ Barriers and resources at work
▸ Planning and initiation of change
(10) Neighbourhood ▸ Barriers and resources in the neighbourhood
▸ Planning and initiation of change
(11) Physical activity with
others
▸ Relevance of physical activity with others
▸ Planning and initiation of change
Focus on consolidation and
relapse prevention
(12) Stigma ▸ Weight-related stigma (eg, critical comments) and
consequences for healthy lifestyle
▸ Social competence training
(13) Stigma and body image ▸ Media messages and stigma
▸ Self-stigma and body image
(14) Motivation and relapse
prevention
▸ Relevance of motivation
▸ Lapse and relapse
▸ Coping with relapse
(15) Consolidation ▸ Repetition of central behaviours for long-term WLM
(16) Certification ▸ Farewell
▸ Conferment of certificates
WLM, weight loss maintenance.
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counselling sessions with a nutritionist over 4 months, in
addition to 60 min weekly or semiweekly physical activity
sessions as described. This TAU is the commonly offered
treatment at the IFB outpatient unit.
Measures
Primary and secondary outcomes
The primary outcome measure is the weight regain (kg)
at 6-month follow-up (t2, 10 months after t0), compared
with pre-treatment weight (t0), both derived from
objectively measured body weight through calibrated
instruments. Weight regain is consistently reported as
the primary outcome measure in WLM trials.9 11 The
secondary outcome of measurement of weight at post-
treatment (t1, 4 months after t0) will provide insight
into the change of the primary outcome over WLM
treatment. Self-report of weight at 12-month follow-up
(t3, 16 months after t0) and at 24-month follow-up (t4,
28 months after t0) will provide evidence of the long-
term maintenance of effects.
Feasibility of the study procedures in general and of
delivering SFM to adults are evaluated by assessing
recruitment, attrition, assessment completion, compli-
ance and patients’ programme evaluation as secondary
outcome measures when appropriate (between pre-
treatment and post-treatment). Further secondary out-
comes include measures of: social and interpersonal
functioning;37–39 eating behaviour;40–42 physical activity;43
psychological and physical symptoms;44–49 and quality of
life.50 The assessments are conducted at pre-treatment
(t0); at post-treatment (t1); and at 6-month, 12-month
and 24-month follow-ups (t2, t3, t4). BMI (kg/m2) is cal-
culated from measured (t0, t1, t2) or self-reported (t3,
t4) weight and height. Further indicators of body fatness
and/or composition and cardiovascular risk are deter-
mined (waist circumference, blood pressure, skinfolds,
bioelectrical impedance analysis: t0, t1, t2).
We chose these outcome measures because they
exhibit good psychometric properties, are well estab-
lished in German and are used in international research
studies. The raters have no therapeutic relationship with
the patients. They underwent extensive training for con-
ducting the assessments and receive ongoing supervision
for standardised administration (drift prevention).
Predictor variables
Predictor variables, assessed at pre-treatment (t0) and
post-treatment (t1), consist of all outcome variables,
sociodemographic variables, compliance, and patient
motivation and expectation ratings assessed through
visual analogue scales.
Methodological aspects
Power analysis
Owing to the preliminary nature of this feasibility trial,
estimation of sample size based on a power analysis was
not deemed necessary. An analysis set consisting of 60
patients (30 patients per study arm) is expected to
provide estimates for changes in weight with a 95% CI of
5 kg. Such precision is more than adequate for a subse-
quent conﬁrmatory trial. This sample calculation is
based on a meta-analysis of extended WLM care versus
no intervention for which a Hedges g of 0.385 is
expected.51 The t-test would then provide a power of
∼55%. Assuming a dropout rate of 20% of patients over
the course of the study, 72 patients are recruited for the
study. This rate is based on dropout rates of 4–24% of
previous WLM treatment studies.52–54 For patients who
discontinue or deviate from the intervention protocol, it
is nevertheless planned to conduct assessments and
complete follow-ups. Efforts to retain as many partici-
pants as possible throughout the study period include
information on the relevance and necessity of the study,
use of continuity forms locating participants throughout
the study period, and use of incentives for follow-up
assessments.
Randomisation
Patients meeting study criteria are enrolled and rando-
mised by trained study staff after giving written informed
consent. To ensure concealment of allocation, the ran-
domisation is centrally performed using an online ran-
domisation tool hosted by the Coordination Center for
Clinical Trials of the University of Leipzig. Randomisation
is based on Pocock’s minimisation algorithm55 and strati-
ﬁed by sex. The allocation ratio between the two study
arms is 1:1.
Blinding
Assessments are performed by independent raters who
have no therapeutic relationship with the patients.
Blinding of treatment to raters and patients is not pos-
sible because of the small scope of this study, and
because patients know the study arm from the particular
modes of delivery.
Data analytic plan
The primary outcome of ‘weight regain at 6-month
follow-up (t2)’ will be investigated by calculating an
effect size with a 95% CI for each arm separately. In add-
ition, a mixed model will be used with weight at
6-month follow-up (t2) as the dependent variable, and
weight at pre-treatment (t0) and study arm as ﬁxed
effects, with the group within study arm as a random
effect. This conﬁrmatory analysis follows the
intent-to-treat principle and will be based on the full
analysis set. Every attempt is made to acquire missing
data. If data missing for the primary outcome can be
expected to bias results in a meaningful way, multiple
imputation will be performed. Further, the analysis of
the primary outcome will be performed in the per-
protocol set to evaluate the treatment effect for patients
with good protocol adherence. The primary outcome
will be further analysed in an exploratory manner as in
the primary analysis, but will also include sex and inter-
vention group.
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Secondary outcomes will be analysed in an explora-
tory, descriptive manner, and will be evaluated by means
of effect sizes, presented with 95% CIs, as well as para-
metric or non-parametric tests, depending on the scale
level and type of distribution of the observed variables.
Maintenance of treatment success over time will be eval-
uated. Predictors of treatment outcome will be identiﬁed
using regression analyses.
Monitoring and data management
The trial is performed in cooperation with the
Coordination Center for Clinical Trials of the University
of Leipzig, which is responsible for monitoring and data
management. After data entry, data are monitored for
completeness, consistency and plausibility. Errors in data
entry are determined in a stepwise procedure, examin-
ing all data of ﬁve patients and, depending on error
rates, examining all data in up to an additional 25% of
the patients. Data quality is ensured through plausibility
checks (eg, examination of ranges). During and after
trial implementation, data will be collected and stored
on servers of the Coordination Center for Clinical Trials,
and thus behind the ﬁrewall of the University of Leipzig.
Access to the servers is secured via https protocol, and
requires user-speciﬁc login and password. Post-treatment
data will be released only after study completion (ie,
after termination of the 24-month follow-up). No
interim analyses are planned. AH will be granted access
to the ﬁnal trial data set. The study data will be reported
in accordance with the extended CONSORT guidelines
for non-pharmacological treatment studies.56
Confidentiality
All clinical data recorded by the trial personnel at the
trial site on paper case report forms will be entered into
the database at the Coordination Center for Clinical
Trials Leipzig by using a trial identiﬁcation number that
does not reference the patient’s personal identiﬁers
(pseudonymised data). In the event of withdrawal of
consent, the necessity for storing data will be evaluated.
Data that are not needed will be deleted as requested,
with full documentation of the reasons for deletion.
Data analysis will be performed solely using de-identiﬁed
data. After trial publication, trial data will be shared in
de-identiﬁed form on request.
Personal information about potential and enrolled
participants collected during enrolment will only be
stored at the trial site and be subject to the raters’ and
therapists’ privacy obligation. Personal information will
not be shared and will be deleted after the trial.
Ethics and dissemination
Ethical approval
The study was approved by the Ethical Committee of
the Medical Faculty at University of Leipzig (165-
13-15072013). Written informed consent is obtained by
trained staff after the study has been fully explained and
prior to randomisation (a model consent form is
available on request). Patients can withdraw at any time
without any disadvantage. The trial is conducted in
accordance to the guidelines for good clinical practice
(GCP).57 All persons participating in the conduct of
the trial commit themselves to the Declaration of
Helsinki (Version Somerset West 1996),58 as well as all
pertinent national laws and the ICH guidelines for GCP
and CPMP/ICH/135/95.59 All protocol modiﬁcations
including changes to eligibility criteria, outcomes or
analyses are reported to the Ethical Committee.
Safety
Adverse events are all unwanted medical events (eg,
emerging or aggravating symptoms) occurring through-
out the trial, whether or not they have a causal associ-
ation with the trial. Adverse events are documented at
every assessment and at every week of treatment
throughout the trial. They are rated according to sever-
ity: serious adverse events are those that led to death,
are life-threatening, make inpatient treatment necessary,
lead to sustained harm, or cause birth defects or
deformities. Serious adverse events include mental or
physical decompensations that indicate a need for hospi-
talisation (eg, acute suicidality). Adverse events are
recorded through a self-report assessment of somatic
symptoms45 46 at pre-treatment (t0) through 6-month
follow-up (t2) and an unstandardised reporting of
adverse events every week during treatment. Any serious
adverse event is immediately reported to the Ethical
Committee of the University of Leipzig. In case of
adverse events making ancillary or post-trial care neces-
sary, participants are referred to local medical care
services.
Owing to the small scope of this exploratory study and
non-psychotherapeutic intervention, an independent
Data Monitoring and Safety Committee was not deemed
to be necessary.
Dissemination
The study results will be disseminated through peer-
reviewed publications and conference presentations to
the scientiﬁc community, and through further presenta-
tions to the public and healthcare professionals. No
restrictions on publication exist. Authorship will follow the
rules of good scientiﬁc practice of the German Research
Foundation, and no professional writers will be used.
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